Pharmacology of bicalutamide
Pharmacokinetics
The pharmacokinetics of bicalutamide are unaffected by food, age, body weight, renal impairment, and mild-to-moderate hepatic impairment. However, it has been observed that steady-state concentrations of bicalutamide are higher in Japanese individuals than in Caucasians, indicating that ethnicity may be associated with differences in the pharmacokinetics of bicalutamide in some instances.

Pharmacology of bicalutamide

Section Title: Pharmacokinetics
Table Section Text: The pharmacokinetics of bicalutamide are unaffected by food, age, body weight, renal impairment, and mild-to-moderate hepatic impairment. However, it has been observed that steady-state concentrations of bicalutamide are higher in Japanese individuals than in Caucasians, indicating that ethnicity may be associated with differences in the pharmacokinetics of bicalutamide in some instances.

50 mg/day	150 mg/day

Cmax	0.77 μg/mL (1.8 μmol/L)	1.4 μg/mL (3.3 μmol/L)

tmax	31 hours	39 hours

Css	8.85 μg/mL (20.6 μmol/L)	21.6–28.5 μg/mL (50.2–66.3 μmol/L)

tss	4–12 weeks	4–12 weeks

Notes: All values are for (R)-bicalutamide. Sources:

Sentence(s)

At steady-state concentrations (Cₛₛ) of (R)-bicalutamide with 50 mg/day and 150 mg/day bicalutamide are 8.85 μg/mL (20.6 μmol/L) and 21.6 μg/mL (50.2 μmol/L).

final_sentence: At steady-state concentrations (Cₛₛ) of (R)-bicalutamide with 50 mg/day and 150 mg/day bicalutamide are 8.85 μg/mL (20.6 μmol/L) and 21.6 μg/mL (50.2 μmol/L).